News September 12, 2024 The project “Nanoworx,” led by Prof. Dr. Willem Mulder, will soon commence under the PharmaNL Shared Development Infrastructure program. Projects in this program aim to establish infrastructure provisions for groundbreaking pharmaceutical products and drug development technologies.
The PharmaNL Shared Development Infrastructure call 2023-1 is the first funding round within the PharmaNL Shared Development Infrastructure (SDI) program line. This program focuses on setting up advanced infrastructures (such as lab equipment) for shared use by pharmaceutical startups, scale-ups, and academic research groups. Establishing such infrastructure is crucial for strengthening the pharmaceutical value chain, as the required R&D facilities and services are currently inadequate or unavailable and do not emerge through normal market forces.
The projects will contribute to expanding and strengthening pharmaceutical hubs, research institutions, and companies with future-proof equipment. This will lead to more efficient and effective development of new drugs and production technologies, shorter lead times, and reduced costs in the pharmaceutical sector.
Prof. Dr. Willem Mulder – TU Eindhoven in collaboration with Trained Therapeutix Discovery and Pivot Park Screening Centre.
To fully harness the potential of nanomedicine, the translation from experimental concepts to innovative nanomedicines for patients must be refined. This requires the establishment of a knowledge and production infrastructure in the field of nanomedicine. By generating nanomedicine libraries, high-throughput screening can identify formulations with the desired properties. Production of these ‘lead’ candidates must then be scaled up according to pharmaceutical quality guidelines. Such infrastructure is currently only available at large biotech and pharmaceutical companies.
Nanoworx integrates advanced equipment and unique expertise to assist research groups and biotech companies in the development, screening, optimization, and upscaling of innovative nanomedicine-based drugs. Expertise and prototype development are provided by engineers and scientists from Eindhoven University of Technology (TU/e). Automated production, library construction, and formulation characterization take place at TU/e. To facilitate clinical translation, Nanoworx collaborates with Pivot Park Screening Centre to guide clients in scaling up GMP-compliant production. In addition to biotech startups and larger firms, Nanoworx will serve academic groups and consortia. Nanoworx is designed to work closely with its clients, ensuring that all knowledge gained is transferred to the client.
Prof. Dr. Ir. Floris Foijer – G2 Solutions in collaboration with UMCG, GenomeScan, LIFE Cooperative, and Pivot Park Screening Centre
Many drugs are not equally effective in all patients, and many patients develop drug resistance, especially in the treatment of chronic or complex diseases such as cancer. New technological developments enable better disease mapping and modeling in the lab. These technologies are therefore essential for improved drug development. G2 Solutions uses these technologies to accurately map diseases and build patient-specific models. This is combined to establish an infrastructure for drug development. The infrastructure will be made available to Dutch pharmaceutical and academic partners. Additionally, G2 Solutions will use the infrastructure itself to collaborate with Pivot Park Screening Centre to discover new drugs. The University Medical Center Groningen will provide personnel, equipment, and laboratory spaces for this, while GenomeScan, LIFE Cooperative, and Pivot Park Screening Centre will help market the services (inter)nationally.
More Information